Published in Vaccine Weekly, August 25th, 2004
This compares with a net loss of $19.1 million, or $0.51 per share, in the same quarter of 2003. Cell Genesys ended the quarter with approximately $173.7 million in cash, cash equivalents, and short-term investments, including restricted cash and investments, and in addition, held approximately 6.6 million shares of its former subsidiary, Abgenix, Inc.
Revenues for the quarter ended June 30, 2004 were $2.5 million compared with revenues of less than $0.1 million recognized for the comparable period in 2003, an increase reflecting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly